Stargardt Disease Therapeutics MarketSize and Trends
Global stargardt disease therapeutics market is estimated to be valued at US$ 213.5 Mn in 2023, and is expected to exhibit a CAGR of 31.7% during the forecast period (2023-2030).
Figure 1. Global Stargardt Disease Therapeutics Market Share (%), By Drug Type, 2023
![](/images/research-%20methodology/541651global-stargardt-disease-therapeutics-market-figure-1.png)
Global Stargardt Disease Therapeutics Market– Drivers
- Increasing positive clinical trials result for the treatmemt of stargardt Disease: Increasing positive clinical trials for the treatment of stargardt disease is promising and offers hope for patients suffering from this rare genetic disorder. Stargardt disease is characterized by the progressive degeneration of the macula that leads tosevere vision loss. The positive results from these clinical trials indicate a potential breakthrough in managing and potentially reversing the effects of this debilitating condition. For instance, on August 9, 2023, Nanoscope Therapeutics Inc., a clinical-stage biotechnology company that focuses on gene therapies for retinal degenerative diseases, announced the key results from its Phase 2 clinical trial, STARLIGHT. As per the result, the patients treated with MCO-010 demonstrated clinically meaningful improvements in best-corrected visual acuity (BCVA).
Figure 2. Global Stargardt Disease Therapeutics Market Share(%), By Region, 2023
![](/images/research-%20methodology/969250global-stargardt-disease-therapeutics-market-figure-2.png)
Global Stargardt Disease Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of things from one place to another.
Global Stargardt Disease Therapeutics Market- Segmentation
Global Stargardt disease therapeutics market report is segmented into by drug type, by age group, by distribution channel, and by region.
- By Drug Type, the market is segmented into Emixustat, LBS-008, and Others (Gildeuretinol). Out of which, the emixustat segment is expected to hold a dominant position in the global stargardt disease therapeutics market during the forecast period due to increasing positive clinical trial results and broader plans for the emixustat by the company.
- By Age Group, the market is segmented into Children (Below 17 Years) and Adult (Above 17 Years). Out of which, Children (Below 17 Years) segment is expected to dominate the market over the forecast period due to increasing children patient pool as compared to the adult patient group.
- By Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Out of which, hospital pharmacies segment is expected to dominate the market over the forecast period andue to increasing management of the stargardt disease by the healthcare professionals.
Among all the segmentation, the drug type segment is expected to dominate the market over the forecast period due to increasing launch of the drugs, collaboration for the market expansion, and also bringing new technology to meet the unmet needs.
Global Stargardt Disease Therapeutics Market: Key Trends
- Funding for the novel treatment of stargardt disease: The funding for the stargardt disease research is the solution to the current challenges, and to generate various new opportunities. By funding stargardt disease research, it may be possible to develop ground-breaking cures and therapies for those who suffer from this crippling affliction. Furthermore, funding for research can also lead to a better understanding of the underlying causes of stargardt disease, paving the way for early detection methods and preventive measures. For instance, in February 2022, SpliceBio, a biotechnology company, received US$ 54.2 Mn (€50M) in series A funding to the boundaries of gene therapy vectors. With this new funding in hand, SpliceBio has firmly established its gene therapy focus, and is creating a pipeline of treatments for genetic blindness conditions. SpliceBio’s lead program has its crosshairs on Stargardt disease, a condition caused by mutations in a retinal gene called ABCA4.